Skip to content

The effect of herbal syrup in the treatment of COVID-19

Evaluation of the Effect of Herbal Syrup on Clinical Outcome of Inpatient with Moderate to Severe COVID-19 Patient

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200721048159N2
Enrollment
66
Registered
2021-04-22
Start date
2021-05-04
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Receiving 15 cc daily, three times a day orally of herbal syrups (each 100 ml of syrup prepared from 10 grams of apples, 15 grams of Lonicera, 15 grams of hyssop an

Sponsors

Khoram-Abad University of Medical Sciences
Lead Sponsor
Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Hospitalized patients suspected to COVID-19 infection who tested positive for PCR or despite the negative PCR test who have a strong clinical evidence plus typical radiographic sing of Covid19 that is difficult to justify their symptoms based on other diseases The presence of respiratory symptoms (including shortness of breath, pain and pressure in the chest) with or without fever equal to or greater than 38 degrees Celsius and SpO2 less than 93%.

Exclusion criteria

Exclusion criteria: Dissatisfaction with the company Discharge of a patient with a criterion other than recovery Admission to another interventional study Need to be admitted to the intensive care unit Occurrence of side effects such as hypersensitivity reactions G6PD deficiency Taking antiplatelet drugs, blood pressure medications, sedatives and barbiturates Receiving cardiac glycosides Hepatic-renal problems Cushing's syndrome Epilepsy

Design outcomes

Primary

MeasureTime frame
Duration of hospitalization. Timepoint: Daily for 5-10 days. Method of measurement: Based on patient file information.

Secondary

MeasureTime frame
The duration of recovery or the duration of entry into the disease stage. Timepoint: Daily for 5-10 days. Method of measurement: Based on patient file information.;Survival rate of 28 days from the time of hospitalization. Timepoint: 28 days after starting the study. Method of measurement: Interview with the patient or her family.;The amount of arterial oxygen saturation. Timepoint: Daily for 5-10 days. Method of measurement: Using a device to measure the percentage of oxygen saturation.;Frequency of transfer to intensive care unit. Timepoint: Daily for 5-10 days. Method of measurement: Under supervision.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForouzan Ahmadpour

Khoram-Abad University of Medical Sciences

ahmadpourforoz@yahoo.com+98 66 3312 0239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026